AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
30 November 2021 - 08:05AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on emerging immune control mechanisms applicable to
inflammation and immuno-oncology indications, today announced the
appointment of Mr. Daniel Faga to the company’s Board of Directors.
“Dan has extensive corporate strategy, finance and public
company leadership experience in building world-class
biopharmaceutical companies,” said Hamza Suria, president and chief
executive officer of AnaptysBio. “His unique strategic vision
is an exciting addition to our Board of Directors and we look
forward to having Dan’s perspective as AnaptysBio continues to
advance multiple wholly-owned clinical and preclinical
first-in-class therapeutic antibody programs.”
Mr. Faga commented, “AnaptysBio has an impressive track-record
of innovating novel therapeutics and is financially well-positioned
to drive potentially transformative medicines over the next several
years. I am excited about AnaptysBio’s future enabled by the
strategic optionality of the company’s pipeline and look forward to
working with the Board and management team.”
Mr. Faga is a seasoned executive with more than 20 years of
industry and advisory experience in the life sciences industry.
Most recently, he was the chief operating officer at Mirati
Therapeutics responsible for leading the company’s strategy,
corporate finance, legal and other business operations. Prior to
Mirati, Dan was chief business officer at Spark Therapeutics until
its acquisition by Roche. Previously, Dan was a managing director
and founding member of Centerview Partner’s healthcare advisory
practice. Dan’s earlier experience includes healthcare investment
banking at Merrill Lynch and management consulting in the life
sciences practice at PRTM. Dan has earned a B.S. in engineering
from Cornell University and an M.B.A. in healthcare
management from the Wharton School of the University of
Pennsylvania.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation. The
Company’s proprietary anti-inflammatory pipeline includes
imsidolimab, its anti-IL-36R antibody, previously referred to as
ANB019, for the treatment of dermatological inflammatory diseases,
including generalized pustular psoriasis, or GPP,
moderate-to-severe acne and moderate-to-severe hidradenitis
suppurativa; rosnilimab, its anti-PD-1 agonist program, previously
referred to as ANB030, for treatment of moderate-to-severe alopecia
areata; and its BTLA modulator program, ANB032, which is broadly
applicable to human inflammatory diseases associated with lymphoid
and myeloid immune cell dysregulation. AnaptysBio’s antibody
pipeline has been developed using its proprietary somatic
hypermutation, or SHM platform, which uses in vitro SHM for
antibody discovery and is designed to replicate key features of the
human immune system to overcome the limitations of competing
antibody discovery technologies. AnaptysBio has also developed
multiple therapeutic antibodies in an immuno-oncology collaboration
with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI
(dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody
(cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody
(GSK4074386), and an inflammation collaboration with Bristol-Myers
Squibb, including an anti-PD-1 checkpoint agonist antibody
(CC-90006) currently in clinical development.
Contacts:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Feb 2024 to Mar 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2023 to Mar 2024